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doi:10.1016/j.jtcvs.2007.02.043bjective: Pulmonary hypertension may complicate surgical correction of congen-
tal heart defects, resulting in increased morbidity and mortality. We have previ-
usly shown that plasma levels of the nitric oxide precursors citrulline and arginine
rop precipitously after congenital cardiac surgery and that oral citrulline supple-
entation may be protective against the development of pulmonary hypertension. In
his study, we assessed the safety and pharmacokinetic profile of intravenous
itrulline as a potential therapy for postoperative pulmonary hypertension.
ethods: The initial phase of this investigation was a dose-escalation study of
ntravenously administered citrulline in infants and children undergoing one of five
ongenital cardiac surgical procedures (phase 1). The primary safety outcome was
20% drop in mean arterial blood pressure from the baseline pressure recorded after
dmission to the intensive care unit. Based on our previous work, the target
irculating plasma citrulline trough was 80 to 100 mol/L. Each patient was given
wo separate doses of citrulline: the first in the operating room immediately after
nitiation of cardiopulmonary bypass and the second 4 hours later in the pediatric
ntensive care unit. Stepwise dose escalations included 50 mg/kg, 100 mg/kg, and
50 mg/kg. After model-dependent pharmacokinetic analysis, we enrolled an addi-
ional 9 patients (phase 2) in an optimized dosing protocol that replaced the
ostoperative dose with a continuous infusion of citrulline at 9 mg/(kg · h) for 48
ours postoperatively.
esults: The initial stepwise escalation protocol (phase 1) revealed that an intrave-
ous citrulline dose of 150 mg/kg given after initiation of cardiopulmonary bypass
ielded a trough level of in the target range of approximately 80 to 100 mol/L 4
ours later. The postoperative dose revealed that the clearance of intravenously
dministered citrulline was 0.6 L/(h · kg), with a volume of distribution of 0.9 L/kg
nd estimated half-life of 60 minutes. Because of the short half-life, we altered the
rotocol to replace the postoperative dose with a continuous infusion of 9 mg/
kg · h). An additional 9 patients were studied with this continuous infusion protocol
phase 2). Mean plasma citrulline levels were maintained at approximately 125
mol/L, with a calculated clearance of 0.52 L/(h · kg). None of the 17 patients
tudied had a 20% drop in mean arterial blood pressure from baseline.
onclusions: In this first report of the use of intravenous citrulline in humans, we found
itrulline to be both safe and well tolerated in infants and young children undergoing
ongenital cardiac surgery. Because of the rapid clearance, the optimal dosing regimen
as identified as an initial bolus of 150 mg/kg given at the initiation of cardiopulmonary
ypass, followed 4 hours later by a postoperative infusion of 9 mg/(kg · h) continued up
o 48 hours. Using this regimen, plasma arginine, citrulline, and nitric oxide metabolite
evels were well maintained. Intravenous citrulline needs to be studied further as a
otential therapy for postoperative pulmonary hypertension.
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Dulmonary hypertension is a potential complication
after surgical correction of congenital cardiac defects
that has been associated with increased postoperative
orbidity and mortality.1-5 Current perioperative treatment
ncludes the use of inhaled nitric oxide and several non-
elective pulmonary vasodilators, including milrinone,
poprostenol, sildenafil citrate (INN sildenafil), and gener-
tion of alkalosis. Another potential therapy includes in-
reasing endogenous nitric oxide synthesis by supplemen-
ation with citrulline or arginine.6,7 Nitric oxide is produced
rom L-citrulline and L-arginine, amino acids generated
hrough the urea cycle (Figure 1).8-10 We have previously
emonstrated that citrulline and arginine levels drop precip-
tously after surgical correction of congenital cardiac de-
ects with cardiopulmonary bypass and do not recover for as
ong as 48 hours after surgery.11 In addition, children with
ostoperative pulmonary hypertension had significantly
ower plasma arginine levels than those without this com-
lication. We subsequently conducted a randomized, placebo-
ontrolled trial of oral citrulline supplementation in this
ame patient population and found that although absorption
as variable, citrulline was safe and that children who had
plasma citrulline level greater than 40 mol/L at 12 hours
fter surgery were free from postoperative pulmonary
ypertension.10
Intravenously administered citrulline has not been previ-
usly studied in human beings. The hypothesis of this study
as that intravenously administered citrulline would be safe
nd would prevent the postoperative drop in plasma citrul-
ine and arginine levels noted in our previous observational
tudies.
aterials and Methods
atient Enrollment
pproval from Vanderbilt’s institutional review board (IRB) was
btained before patient enrollment. A total of 17 patients were
nrolled in this open-label dose-escalation study at Vanderbilt
hildren’s Hospital between May 2005 and January 2006.
All infants or children younger than 6 years undergoing one
f five surgical procedures for correction of congenital heart
esions were considered for enrollment. The eligible surgical
rocedures were as follows: (1) repair of atrioventricular septal
efect, (2) repair of ventricular septal defect, (3) bidirectional
lenn procedure (superior cavopulmonary shunt), (4) modified
ontan procedure (total cavopulmonary connection), and (5)
rterial switch procedure. Exclusion criteria were as follows:
1) significant pulmonary arterial narrowing not addressed sur-
ically, (2) previous pulmonary artery stent placement, (3)
revious pulmonary artery angioplasty, (4) significant left-sided
trioventricular valve regurgitation, (5) pulmonary venous re-
urn abnormalities, (6) pulmonary vein stenosis, (7) preopera-
ive mechanical ventilation, and (8) preoperative inotropic
nfusions.
Informed written consent was obtained from parents of the
nrolled patients during preoperative evaluation at the Cardiotho- (
20 The Journal of Thoracic and Cardiovascular Surgery ● Auguacic Surgery Clinic (outpatient) or at Vanderbilt Children’s Hos-
ital (inpatient). Three cardiac surgeons at Vanderbilt Children’s
ospital (K.G.C., D.C.D., F.S.) performed the surgical proce-
ures with similar cardiopulmonary bypass and cardioplegia
reparations.
This study was monitored closely by a data safety monitoring
oard (DSMB) composed of a pediatric cardiologist, a pediatric
ritical care physician, and a general pediatrician. The DSMB met
hree times during the study to review the safety and pharmaco-
inetic data.
dverse Events
ntravenous citrulline administration carries a theoretic risk of
ystemic arterial hypotension. An adverse drop in mean arterial
ressure was defined as a decrease of more than 20% from base-
ine. The baseline postoperative mean arterial blood pressure was
alculated as the average of mean arterial blood pressure measure-
ents collected every 5 minutes for the 30 minutes immediately
efore the administration of the postoperative dose or infusion.
he bedside monitor was then set to alarm if that 20% drop was
eached at any time in the 48-hour study period. If the bedside
onitor reached the preset limit and alarmed, the beside nurse was
nstructed to alert the study physician or nurse and to record mean
rterial pressure every 5 minutes for 30 minutes. If the average of
hese 5-minute recordings was 20% below the original baseline
lood pressure, the citrulline was discontinued. Patients were
reated for hypotension at the discretion of the clinical pediatric
ntensive care unit (PICU) staff with volume resuscitation, inotro-
ic or vasopressor support, or both. Development of hypotension
ccording to these criteria that necessitated discontinuation of
itrulline was counted as an adverse event and was reported to the
SMB, IRB, and Food and Drug Administration (FDA).
Serious adverse events, such as cardiac arrest, need for extra-
orporeal membrane oxygenation, and death, were reported imme-
iately to the DSMB, the Vanderbilt IRB, and the FDA.
tudy Protocol
he study design for the first 8 patients (phase 1) was a dose-
scalation protocol with two intravenously administered bolus
oses of citrulline to determine the optimal dose and characterize
harmacokinetic parameters including half-life, clearance, and
olume of distribution. The first bolus (given during the course of
0 minutes) was administered after initiation of cardiopulmonary
ypass in the operating room; and the second (given during the
ourse of 30 min) was administered 4 hours later in the critical care
nit. The intravenous doses of citrulline for each bolus were 50
g/kg (2 patients), 100 mg/kg (2 patients), and 150 mg/kg
Abbreviations and Acronyms
DSMB data safety monitoring board
FDA  Food and Drug Administration
IRB  institutional review board
krem  constant of citrulline removal
PICU  pediatric intensive care unit
Rapp  rate of citrulline appearance4 patients).
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DThe study design was changed (phase 2) after it was determined
hat the half-life and clearance were not compatible with intermit-
ent dosing. After consultation with a pharmacologist, the next 9
atients received a 150-mg/kg intravenously administered bolus of
itrulline during the course of 10 min in the operating room after
nitiation of cardiopulmonary bypass, followed 4 hours later in the
ritical care unit by a continuous infusion of 9 mg/(kg · h) that
ontinued for 48 hours.
The citrulline preparation was provided by the Investigational
rug Service of the Vanderbilt Hospital Clinical Pharmacy. Cit-
ulline was administered as a 50-mg/mL (5%) isotonic solution,
ith distilled water as a suspending agent.
ample Collection
3-mL sample of blood was obtained from each patient at
elected time points. In phase 1, samples were collected immedi-
tely after initiation of cardiopulmonary bypass before the first
olus given in the operating room, postoperatively 4 hours after the
perating room bolus (immediately before the postoperative bo-
us), and then 1, 2, 3, 4, and 12 hours after the postoperative bolus.
n phase 2, samples were collected immediately after initiation of
ardiopulmonary bypass (before the first bolus given in the oper-
ting room), immediately after the operating room bolus, postop-
ratively 4 hours after the operating room bolus (immediately
Figure 1. Carbamyl phosphate synthetase I (CPSI) is ra
alter availability of nitric oxide precursors, citrulline,
is then metabolized into either nitric oxide (NO) by nit
Bicarbonate; NH4 , ammonium; ATP, adenosine tripho
cinate synthetase; ASL, argininosuccinate lyase. From
FG, Christman BW, et al. Nitric oxide precursors and c
citrulline. J Thorac Cardiovasc Surg. 2006;132:58-65.efore the postoperative infusion), and then 6, 12, 24, and 48 hours m
The Journal of Thoracicfter initiation of the postoperative continuous infusion. Samples
ere collected in citrated tubes, placed on ice, and stored at 4°C
ntil processing. Samples were centrifuged for separation of
lasma and cellular components. Plasma samples were frozen at
70°C until further laboratory analysis.
aboratory Measurements
oncentrations of plasma citrulline and arginine were determined
hrough amino acid analysis by cation-exchange chromatography
ith a Beckman 7300 amino acid analyzer (Beckman Coulter, Inc,
ullerton, Calif). Calibration of the analyzer with known standards
as completed before testing of patient samples.
Nitric oxide metabolites were measured by chemiluminescence
ith a Sievers 280 nitric oxide analyzer (GE Analytical Instru-
ents, Boulder, Colo). Plasma samples were mixed 1:2 sample/
old ethanol at 0°C for 30 minutes. After centrifugation at 14,000
pm for 5 minutes, samples were injected into the analyzer. This
ethod relies on catalytic reduction of nitric oxide metabolites
y exposure to warm vanadium hydrochloride. Liberated nitric
xide was driven by nitrogen gas into an ozone chamber. Light
eleased by nitric oxide– ozone interaction was captured by a
hotomultiplier tube and relayed to an analytic software pro-
ram. A standard curve with sodium nitrite was used to deter-
miting enzyme of urea cycle. Polymorphisms in its gene
arginine. Citrulline is metabolized into arginine, which
ide synthetase (NOS) or urea by arginase (ARG). HCO3 ,
te; OTC, ornithine transcarbamylase; ASS, argininosuc-
ith HA, Canter JA, Christian KG, Drinkwater DC, Scholl
nital heart surgery: a randomized controlled trial of oralte-li
and
ric ox
spha
Sm
ongeine sample concentrations.
and Cardiovascular Surgery ● Volume 134, Number 2 321
P
D
p
b
T
p
e
b
a
e
d
S
fi
o
d
v
R
P
S
p
6
5
f
p
t
i
s
S
T
w
u
a
p
s
w
t
p
i
f
w
r
2
s
c
r
H
P
i
t
l
c
d
c
a

w
t
c
c

t
a
8
p
8
t
c
t
p
h
w
T
a
O
(
b
c
p
(
e
i
b
P
t
T
F
F
d
t
v
d
p
o
Surgery for Congenital Heart Disease Barr et al
3
CH
Dharmacokinetic Analysis
ata obtained for each patient in phase 1 were fitted to the
harmacokinetic model depicted in Figure 2. In this model, the
ody exists as a single compartment with a volume of distribution.
he appearance of citrulline in plasma is described by a zero-order
rocess (rate of citrulline appearance, Rapp) to account for endog-
nous production, whereas the removal of citrulline is determined
y a first-order process (constant of citrulline removal, krem). It is
ssumed that the values of all parameters remained constant for
ach patient during the course of plasma sampling. Mass–balance
ifferential equations were inputted into SCIENTIST (MicroMath
cientific Software, St Louis, Mo) and solved numerically. Data
tting was accomplished by a weighted, least squares procedure to
btain the simultaneous estimates of Rapp, krem, and volume of
istribution. Clearance was calculated from krem multiplied by the
olume of distribution, and half-life was estimated as ln2/krem.
esults
atient Enrollment
eventeen patients were successfully enrolled, 8 patients in
hase 1 and 9 in phase 2. The median age of the patients was
months (interquartile range 3.6 –30.6 months), with
5% male and 81% white. Surgical interventions were as
ollows: 4 patients with ventricular septal defect repair, 8
atients with atrioventricular septal defect repair, 2 pa-
ients with bidirectional Glenn shunt, 1 patient with mod-
fied Fontan procedure, and 2 patients with arterial
witch.
afety
here were no significant adverse events in phase 1. There
as 1 significant adverse event in phase 2. That patient
nderwent an atrioventricular septal defect repair and was in
junctional rhythm postoperatively, necessitating atrial
acing. At approximately 8 postoperative hours, the patient
howed the acute onset of profound bradycardia consistent
ith complete heart block that was not preceded by sys-
emic hypotension and was not responsive to ventricular
igure 2. Pharmacokinetic model used in analysis of phase 1
ata and for design of phase 2 intravenous (IV) dosing regimen. In
his model, body is represented as single compartment with
olume of distribution (Vd). Citrulline appearance in plasma is
escribed by zero-order process (Rapp) to account for endogenous
roduction, whereas removal from plasma is determined by first-
rder process (krem).acing. Advanced life-support measures were instituted, c
22 The Journal of Thoracic and Cardiovascular Surgery ● Auguncluding open cardiac massage and emergency cannulation
or venoarterial extracorporeal membrane oxygenation,
hich was required for 48 hours. The patient subsequently
ecovered fully and was discharged home on hospital day
2. The DSMB reviewed the case and determined that the
ignificant adverse event was unlikely to be related to the
itrulline administration. The adverse event was also
eported to the Vanderbilt IRB, the National Institutes of
ealth, and the FDA.
harmacokinetics
Phase 1. Patients in phase 1 were given two doses of
ntravenously administered citrulline, the first just after ini-
iation of cardiopulmonary bypass and the second 4 hours
ater after admission to the PICU. The plasma levels of
itrulline at the various times after drug administration are
epicted in Figure 3. Patients 1 and 2 received 50-mg/kg
itrulline intravenously and had a peak citrulline level of
pproximately 220 mol/L and a 4-hour trough level of 40
mol/L. No adverse side effects were noted. This trough
as well below the target range of 80 to 100 mol/L, and
he dose was subsequently increased. Patients 3 and 4 re-
eived 100-mg/kg citrulline intravenously and had a peak
itrulline level of 375 mol/L and a 4-hour trough of 50
mol/L. Again, no adverse side effects were noted. This
rough was also below the target range of 80 to 100 mol/L,
nd the dose was subsequently increased. Patient 5, 6, 7, and
received 150 mg/kg citrulline intravenously and had a
eak citrulline level of 660 mol/L and a 4-hour trough of
0 mol/L. This 4-hour trough was in the target range of 80
o 100 mol/L, and the dose was not escalated further. The
itrulline pharmacokinetic parameter estimates for each of
he three dosage levels are summarized in Table 1, and the
harmacokinetic profiles are displayed in Figure 3. The
alf-life was calculated to be approximately 60 minutes,
hich was too short to proceed with intermittent dosing.
he study design was changed to a bolus dose followed by
continuous infusion in phase 2.
Phase 2. An additional 9 patients were enrolled in phase 2.
n the basis of parameter estimates obtained from phase 1
Table 1), pharmacokinetic simulations predicted that a
olus dose of 150 mg/kg followed 4 hours later by a
ontinuous infusion of 9 mg/(kg · h) would yield sustained
lasma citrulline levels of approximately 80 to 100 mol/L
Figure 4). Initiation of the continuous infusion was delib-
rately set at 4 hours after the bolus to allow sustained
ncreased levels during separation from cardiopulmonary
ypass and ultrafiltration, to allow time for admission to the
ICU, and to allow postoperative hemodynamic stabiliza-
ion to allow accurate assessment of the drug safety profile.
he phase 2 mean plasma citrulline profile is shown in
igure 5. For the entire group, postoperative mean plasma
itrulline levels were sustained at approximately 150 to 250
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Dmol/L during the 48-hour study period. Estimated citrul-
ine clearance was 0.52  0.28 L/(kg · h) in phase 2. The
ean plasma citrulline levels of a previously published
ohort of patients undergoing congenital cardiac surgery
ho had not received intravenously administered citrulline
re also depicted in Figure 5 for comparison.11 Figure 6
epicts similar data for plasma arginine levels, which were
lso sustained after intravenous administration of citrulline
elative to data from the previous cohort.11 Figure 7 depicts
imilar data for plasma nitric oxide metabolite levels, which
ere also sustained after intravenous administration of cit-
ulline relative to data from the previous cohort.11
iscussion
his is the first report of the use of intravenously adminis-
ered citrulline in human beings. The goal of this study was
o determine the safety profile and pharmacokinetics of
ntravenously administered citrulline in a fairly unique pa-
ient population of infants and children undergoing surgical
orrection of congenital heart defects. This was an open-
abel study that was not placebo controlled and thus not
esigned to evaluate the use of intravenously administered
itrulline as a potential therapy for postoperative pulmonary
ypertension. The pharmacokinetic and safety information
ained from this study, however, has been subsequently
sed to design a randomized, placebo-controlled efficacy
rial of intravenously administered citrulline for the treat-
ent of postoperative pulmonary hypertension.
With regard to safety, we were primarily interested in
ystemic hypotension as a potential negative side effect of
itrulline treatment. We defined systemic hypotension as a
ustained 20% drop in mean arterial pressure from an av-
rage baseline recording that was obtained during the 30
inutes just before initiation of intravenous citrulline ad-
inistration, either as a bolus (phase 1) or as a continuous
nfusion (phase 2). This definition took into account some of
he inherent blood pressure variation in children immedi-
tely after congenital cardiac surgery. None of the patients
n phase 1 met this definition of systemic hypotension. Only
patient in phase 2 of this study met this definition, and that
atient’s hypotension was precipitated by profound brady-
ardia and heart block, a side effect unlikely to be precipi-
ated by citrulline. The DSMB reviewed that patient’s clin-
cal data and determined that the adverse event was unlikely
o be related to the citrulline infusion. The Vanderbilt IRB,
he National Institutes of Health, and the FDA were also
otified and concurred with this conclusion.
The pharmacokinetics of intravenously administered cit-
ulline in this patient population are significantly compli-
ated by the interposition of cardiopulmonary bypass and
ltrafiltration. We initially decided to administer a fairly
arge bolus of citrulline immediately after initiation of car-igure 3. Pharmacokinetic profile of intravenously administered
IV) bolus-dose citrulline in phase 1. Dose-escalation study de-
ign in which each patient was given two boluses of citrulline,
rst in operating room (OR) on cardiopulmonary bypass and
econd 4 hours later after admission to pediatric intensive care
nit (PICU). Patients 1 and 2 received 50 mg/kg (A), patients 3 and 4
eceived 100 mg/kg (B), and patients 5, 6, 7, and 8 received 150iopulmonary bypass, with the goal of providing a 4-hour
and Cardiovascular Surgery ● Volume 134, Number 2 323
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Darget trough level of approximately 80 to 100 mol/L. This
arget level was intentionally above the threshold value of
pproximately 40 mol/L that we had previously identified
s potentially protective against postoperative pulmonary
ypertension in our studies with orally administered citrul-
ine.10 With an intravenously administered citrulline bolus
f 150 mg/kg, we were able to achieve that target 4-hour
rough level. An alternative approach would have been to
se a smaller initial bolus followed by an immediate con-
inuous infusion, but the mechanics of cardiopulmonary
ypass and ultrafiltration both during and after bypass made
his approach impractical.
In phase 1 of the study, we determined that the half-
ife of intravenously administered citrulline is fairly short
t approximately 60 minutes. The volume of distribution
f citrulline was estimated between 0.8 and 1.0 L/kg
mong the dosage groups in Phase 1 (Table 1). This value
uggests that citrulline distributes to extravascular
paces. The high postdosing levels observed during phase
suggest that citrulline rapidly distributes out of the
Figure 4. Pharmacokinetic modeling of intravenously adm
followed 4 hours later by continuous infusion. Bolus dose
ABLE 1. Model-dependent citrulline pharmacokinetic par
Patients 1 an
Dose (mg/kg) 50
Rapp (mol/[h · kg]) 19.1 (15.9, 22
krem (h
1) 0.78 (0.67, 0.
Volume of distribution (L/kg) 0.99 (0.97, 1.
Clearance (L/[h · kg]) 0.78 (0.65, 0.
ata represent means of individual values ( SD for patients 5 through 8
nd 4) of parameter estimates from pharmacokinetic model shown in Figuof 80 to 100 mol/L, and infusion of 9 mg/(kg · h) was predicted t
24 The Journal of Thoracic and Cardiovascular Surgery ● Auguascular space. The short half-life of citrulline is largely
ue to efficient elimination by the body, with clearance
.6 to 0.8 L/(kg · h).
We did not study intravenously administered citrulline
n patients who were not undergoing cardiac surgery.
ith computer modeling of data obtained from the sec-
nd postoperative bolus dose in phase 1 of this study,
owever, we estimated that a bolus of 20 mg/kg immedi-
tely followed by a continuous infusion of 9 mg/(kg · h)
ould rapidly achieve steady state at plasma levels of 100
mol/L in other patient groups at risk for pulmonary hy-
ertension, in whom the effects of cardiopulmonary bypass
ould not be a concern in establishing the pharmacokinetics
f citrulline. This noncardiac surgical protocol would need
o be validated in further studies.
Determination of whether intravenously administered
itrulline is a potential therapy for postoperative pulmonary
ypertension will require a randomized clinical trial. We
ave recently initiated a trial of intravenously administered
itrulline versus saline placebo according the described pro-
ered (IV) bolus of citrulline given at beginning of surgery,
mg/kg was determined most likely to yield 4-hour trough
ter estimates
Patients 3 and 4 Patients 5-8
100 150
14.7 (13.4, 16.0) 10.8 1.9
0.72 (0.87, 0.56) 0.68 0.16
0.99 (0.77, 1.22) 0.89 0.24
0.68 (0.67, 0.8) 0.58 0.05
idual values are given in parentheses for patients 1 and 2 and patients 3
Rapp , Rate of citrulline appearance; krem , constant of citrulline removal.inist
of 150ame
d 2
.2)
89)
02)
91)
; indivo achieve steady state. This protocol was used in phase 2.
st 2007
t
c
i
I
i
p
u
n
R
F
P
n
l
l
c
m
g
o
F
P
n
l
l
p
p
study are shown.11
F
t
c
c
9
i
p
c
Barr et al Surgery for Congenital Heart Disease
The Journal of Thoracic
CH
Docol in infants and children undergoing these same five
ardiac surgical procedures, with a goal of reducing the
ncidence of postoperative pulmonary hypertension by 50%.
n addition, the efficacy of combination therapy of orally or
ntravenously administered citrulline and other therapies for
ulmonary hypertension, such as inhaled nitric oxide, neb-
lized inhaled epoprostenol, and orally administered silde-
afil citrate, should be investigated.
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igure 7. Plasma concentration–time profile of nitric oxide me-
abolites (NOx) in phase 2. Patients 9 to 17 were administered
itrulline 150 mg/kg intravenously (IV) in operating room on
ardiopulmonary bypass, followed by continuous infusion at
mg/(kg · h) initiated 4 hours later after admission to pediatric
ntensive care unit. For comparison, nitric oxide metabolite
lasma levels in infants undergoing similar procedures without
itrulline treatment in previously published study are shown.10igure 5. Plasma concentration–time profile of citrulline in phase 2.
atients 9 to 17 were administered citrulline 150 mg/kg intrave-
ously (IV) in operating room on cardiopulmonary bypass, fol-
owed by continuous infusion at 9 mg/(kg · h) initiated 4 hours
ater after admission to pediatric intensive care unit. Target
itrulline levels were achieved with this citrulline dosing regi-
en. For comparison, citrulline plasma levels in infants under-
oing similar procedures without citrulline treatment in previ-
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